248 related articles for article (PubMed ID: 6783355)
21. A human myeloma cell line that does not express immunoglobulin but yields a high frequency of antibody-secreting hybridomas.
Pickering JW; Gelder FB
J Immunol; 1982 Jul; 129(1):406-12. PubMed ID: 6806365
[TBL] [Abstract][Full Text] [Related]
22. [Immunofluorescence optical studies for the differentiation of monoclonal and polyclonal increases in immunoglobulin producing bone marrow cells].
Morell A; Mosimann W; Skvaril F; Barandun S
Schweiz Med Wochenschr; 1974 Sep; 104(39):1395-6. PubMed ID: 4214489
[No Abstract] [Full Text] [Related]
23. Pseudo-gamma heavy chain (IgG4 lambda) deposition disease.
Tubbs RR; Berkley V; Valenzuela R; McMahon JT; Gephardt GN; Fishleder AJ; Nally JV; Pohl MA; Bukowski RM; Lichtin AE
Mod Pathol; 1992 Mar; 5(2):185-90. PubMed ID: 1574496
[TBL] [Abstract][Full Text] [Related]
24. [Deposition of light chains in various organs; light chain deposition disease].
van Klaveren RJ; Holdrinet RS; Assmann KJ
Ned Tijdschr Geneeskd; 1989 May; 133(18):943-6. PubMed ID: 2498673
[TBL] [Abstract][Full Text] [Related]
25. Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.
Hutchison CA; Plant T; Drayson M; Cockwell P; Kountouri M; Basnayake K; Harding S; Bradwell AR; Mead G
BMC Nephrol; 2008 Sep; 9():11. PubMed ID: 18808676
[TBL] [Abstract][Full Text] [Related]
26. Morphologic heterogeneity of renal light-chain deposition disease.
Gokden N; Barlogie B; Liapis H
Ultrastruct Pathol; 2008; 32(1):17-24. PubMed ID: 18300034
[TBL] [Abstract][Full Text] [Related]
27. The mouse myeloma system. A model for studying the effect of malignant transformation on immunoglobulin production.
Baumal R; Percy M
Isr J Med Sci; 1977 Aug; 13(8):777-96. PubMed ID: 408295
[No Abstract] [Full Text] [Related]
28. Messenger RNA from allotype-defined rabbits directing the cell-free synthesis of immunoglobulin heavy and light chains.
Pavirani A; Mage R; Fitzmaurice L
Eur J Immunol; 1982 Jun; 12(6):485-90. PubMed ID: 6811285
[TBL] [Abstract][Full Text] [Related]
29. Two myeloma globulins IgG1-kappa and IgG1-lambda, from a single patient (Im). II. Their common cellular origin as revealed by immunofluorescence studies.
Bouvet JP; Buffe D; Oriol R; Liacopoulos P
Immunology; 1974 Dec; 27(6):1095-101. PubMed ID: 4141694
[TBL] [Abstract][Full Text] [Related]
30. Murine heavy chain disease.
Morrison SL
Eur J Immunol; 1978 Mar; 8(3):194-9. PubMed ID: 95958
[TBL] [Abstract][Full Text] [Related]
31. Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management.
Bridoux F; Javaugue V; Bender S; Leroy F; Aucouturier P; Debiais-Delpech C; Goujon JM; Quellard N; Bonaud A; Clavel M; Trouillas P; Di Meo F; Gombert JM; Fermand JP; Jaccard A; Cogné M; Touchard G; Sirac C
Kidney Int; 2017 Feb; 91(2):423-434. PubMed ID: 27773425
[TBL] [Abstract][Full Text] [Related]
32. Immunoglobulin light chain nephropathies.
Sturgill BC; Tucker FL; Bolton WK
Pathol Annu; 1987; 22 Pt 2():133-50. PubMed ID: 3120137
[TBL] [Abstract][Full Text] [Related]
33. Cytoplasmic heavy and light chain isotypic suppression by peripheral Fc gamma + T-cells from multiple myeloma.
Guglielmo P; Cunsolo F; Milone G; Di Raimondo F; Giustolisi R; Cacciola E
Haematologica; 1987; 72(5):465-8. PubMed ID: 2961667
[No Abstract] [Full Text] [Related]
34. [Light chain or monoclonal immunoglobulin deposit disease. Apropos of a case associated with light chain myeloma].
Clerc D; Delfraissy JF; Delrieu F; Amoudry C; Bisson M; Massias P
Rev Rhum Mal Osteoartic; 1985 Jan; 52(1):51-6. PubMed ID: 3922045
[No Abstract] [Full Text] [Related]
35. [Rule of antibody structure: the primary structure of a human monoclonal IgA1-immunoglobulin (myeloma protein Tro), I. Purification and characterization of the protein and its L- and H-chains (author's transl)].
Kortt A; Ruban E; Scholz R; Kratzin H; Götz H; Hilschmann N
Hoppe Seylers Z Physiol Chem; 1978 Dec; 359(12):1681-8. PubMed ID: 104912
[TBL] [Abstract][Full Text] [Related]
36. [Non-amyloid nephrotic syndrome: first isolated manifestation of a kappa light chain myeloma (author's transl)].
Mignon F; Vasmant D; Richet G; Wang A; Morel-Maroger L; Brouet JC
Ann Med Interne (Paris); 1979; 130(11):513-6. PubMed ID: 121516
[TBL] [Abstract][Full Text] [Related]
37. IgA1 half molecules in human multiple myeloma and the in vitro production of similar fragments from intact IgA1 molecules.
Biewenga J; Van Loghem E
Clin Exp Immunol; 1983 Feb; 51(2):395-400. PubMed ID: 6839548
[TBL] [Abstract][Full Text] [Related]
38. [Light-chain deposition disease. Presentation of a case].
Bertoli G; Ghiringhelli P; Bersiga A; Pecchini F; Betri E
Pathologica; 1989; 81(1072):203-11. PubMed ID: 2505215
[TBL] [Abstract][Full Text] [Related]
39. [Intracytoplasmic crystals and Fanconi syndrome in a patient with IgA kappa myeloma].
Martín Reyes G; García González I; Alférez MJ; Martínez González JM; Frutos MA
Nefrologia; 2001; 21(2):213-6. PubMed ID: 11464657
[TBL] [Abstract][Full Text] [Related]
40. Development of rapidly progressive liver light chain deposition under VAD chemotherapy in multiple myeloma.
Samanez C; Domingo A; Cibeira MT; Miquel R; Soler M; Bladé J
Eur J Haematol; 2006 Jan; 76(1):83-5. PubMed ID: 16343276
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
